INDV · Categories · Form 4

INDV - SEC Form 4 insider transactions

Indivior Pharmaceuticals Inc. (INDV) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for INDV

• 25d
  Director Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 25d
  Director Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 25d
  Director Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 25d
  Director Ninivaggi Daniel A was granted 6,518 shares, increasing direct ownership by 32% to 27,163 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 25d
  Director Ryan Barbara was granted 6,518 shares, increasing direct ownership by 114% to 12,242 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 25d
  Director Stejbach Mark was granted 6,518 shares, increasing direct ownership by 32% to 27,087 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 25d
  Director Wheadon David E. was granted 10,430 shares, increasing direct ownership by 51% to 30,780 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 83d
  Chief Financial Officer Preblick Ryan converted options into 6,302 shares and covered exercise/tax liability with 2,843 shares, increasing direct ownership by 1% to 320,751 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 95d
  Chief Accounting Officer Anderson Woodrow D converted options into 24,310 shares and covered exercise/tax liability with 10,965 shares, increasing direct ownership by 118% to 24,638 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 95d
  Chief Financial Officer Preblick Ryan covered exercise/tax liability with 87,597 shares and converted options into 86,949 shares, decreasing direct ownership by 0.20% to 317,292 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 95d
  Chief Legal Officer Burris Jeffrey W converted options into 79,893 shares and covered exercise/tax liability with 36,032 shares, increasing direct ownership by 159% to 71,518 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 95d
  Chief Scientific Officer Heidbreder Christian converted options into 101,544 shares and covered exercise/tax liability with 45,797 shares, increasing direct ownership by 29% to 246,509 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 116d
  Chief Accounting Officer Anderson Woodrow D was granted 6,903 shares, increasing direct ownership by 157% to 11,293 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 116d
  Chief Financial Officer Preblick Ryan was granted 37,358 shares, increasing direct ownership by 13% to 317,940 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 116d
  Chief Legal Officer Burris Jeffrey W was granted 26,897 shares, increasing direct ownership by 3,539% to 27,657 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 116d
  Chief Scientific Officer Heidbreder Christian was granted 33,622 shares, increasing direct ownership by 21% to 190,762 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 116d
  Chief Commercial Officer Barry Patrick A was granted 31,380 shares (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 116d
  Chief Executive Officer Ciaffoni Joseph was granted 79,976 shares, increasing direct ownership by 143% to 135,976 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 131d
  Director Kingsley Stuart A was granted 3,722 shares, increasing direct ownership by 405% to 4,642 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 131d
  Director Wheadon David E. was granted 5,955 shares, increasing direct ownership by 41% to 20,350 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 131d
  Director Ryan Barbara was granted 3,722 shares, increasing direct ownership by 190% to 5,685 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 131d
  Director Ninivaggi Daniel A was granted 3,722 shares, increasing direct ownership by 22% to 20,645 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 131d
  Director Stejbach Mark was granted 3,722 shares, increasing direct ownership by 22% to 20,569 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 131d
  Director Thompson Juliet was granted 3,722 shares, increasing direct ownership by 97% to 7,572 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
• 131d
  Director Humphreys Keith was granted 3,722 shares, increasing direct ownership by 64% to 9,524 units (SEC Form 4)

  4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

Other INDV categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends